Danirixin is a selective, and reversible CXCR2 antagonist, with IC50 of 12.5 nM for CXCL8.
Danirixin is a small molecule, CXCR2 antagonist being evaluated as a potential anti-inflammatory medicine[1].
References:
[1]. Miller BE, et al. The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist--in healthy adult subjects. BMC Pharmacol Toxicol. 2015 Jun 20;16:18.